Patents by Inventor Paul H. C. Mundill

Paul H. C. Mundill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7534393
    Abstract: A fertility determining system employing hormone level measuring apparatus on selected days in a menstrual cycle to determine the levels of analytes, i.e., estrone-3-glucuronide (“E3G”) and luteinizing hormone (“LH”), in early morning urine. The fertility/infertility signalling algorithm relies upon data characterizing the user earlier in that menstrual cycle, and also upon her analyte pattern in past recent cycles. At a point in a menstrual cycle which is user-dependent, the early morning E3G urine level is compared against the lower E3G level earlier in the cycle. The beginning of the fertile period is signalled when a sufficient E3G increase occurs. The end of the fertile period (and, correspondingly, the reestablishment of a period requiring no contraception) is signalled a period after the LH surge. In the absence of an LH surge in any subject, the end of the fertile phase is signalled a period of time following the peak of the E3G urinary metabolite of estradiol.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: May 19, 2009
    Assignee: Inverness Medical Switzerland GmbH
    Inventors: Michael Catt, Carole R. Cunningham, Paul H. C. Mundill, Michael E. Prior, Stewart Wilson, Zhi G. Zhang
  • Patent number: 6927064
    Abstract: A fertility determining system employing hormone level measuring apparatus on selected days in a menstrual cycle to determine the levels of analytes, i.e., estrone-3-glucuronide (“E3G”) and luteinizing hormone (“LH”), in early morning urine. The fertility/infertility signalling algorithm relies upon data characterizing the user earlier in that menstrual cycle, and also upon her analyte pattern in past recent cycles. At a point in a menstrual cycle which is user-dependent, the early morning E3G urine level is compared against the lower E3G level earlier in the cycle. The beginning of the fertile period is signalled when a sufficient E3G increase occurs. The end of the fertile period (and, correspondingly, the reestablishment of a period requiring no contraception) is signalled a period after the LH surge. In the absence of an LH surge in any subject, the end of the fertile phase is signalled a period of time following the peak of the E3G urinary metabolite of estradiol.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: August 9, 2005
    Assignee: Inverness Medical Switzerland GmbH
    Inventors: Michael Catt, Carole R. Cunningham, Paul H. C. Mundill, Michael E Prior, Stewart Wilson, Zhi G. Zhang